KILITCH.NS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 11:59):

Stats
Dagens volum	23 004.00
Gjennomsnittsvolum	10 730.00
Markedsverdi	5.96B
EPS	INR0 ( 2024-02-08 )
Neste inntjeningsdato	( INR0 ) 2024-05-27
Last Dividend	INR0.500 ( 2019-09-20 )
Next Dividend	INR0 ( N/A )
P/E	40.19
ATR14	INR2.00 (0.54%)

Volum Korrelasjon

Lang: 0.13 (neutral)

Kort: 0.24 (neutral)

Signal:(50.674) Neutral

Kilitch Drugs (India) Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Kilitch Drugs (India) Korrelasjon - Valuta/Råvare

-0.35
( neutral )

0.34
( neutral )

-0.42
( neutral )

0.09
( neutral )

0.59
( weak )

-0.64
( weak negative )

Kilitch Drugs (India) Økonomi

Annual	2022
Omsetning:	INR1.40B
Bruttogevinst:	INR648.40M (46.45 %)
EPS:	INR6.71

FY	2022
Omsetning:	INR1.40B
Bruttogevinst:	INR648.40M (46.45 %)
EPS:	INR6.71

FY	2022
Omsetning:	INR1.14B
Bruttogevinst:	INR488.01M (42.72 %)
EPS:	INR4.73

FY	2021
Omsetning:	INR685.23M
Bruttogevinst:	INR312.16M (45.56 %)
EPS:	INR2.37

Financial Reports:

No articles found.

Kilitch Drugs (India) Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Kilitch Drugs (India) Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.64 - low (54.24%) | Divividend Growth Potential Score: 4.46 - Potential for dividend initiation, but uncertain (10.73%)

Information

First Dividend	INR1.000	2010-10-14
Last Dividend	INR0.500	2019-09-20
Next Dividend	INR0	N/A
Payout Date	2019-10-30
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	INR33.00	--
Avg. Dividend % Per Year	0.00%	--
Score	1.62	--
Div. Sustainability Score	4.64
Div.Growth Potential Score	4.46
Div. Directional Score	4.55	--

Next Divdend (Est)
(2025-09-01)

INR0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

1.62

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.500	0.59%
2019	INR0.500	0.31%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SHANTIGEAR.NS	Dividend Junior	2023-07-11	Annually	23	1.02%
MANGCHEFER.NS	Dividend Junior	2023-09-18	Annually	17	1.18%
GRANULES.NS	Dividend Junior	2023-08-03	Semi-Annually	20	0.29%
BAJAJCON.NS	Dividend Junior	2023-08-02	Annually	14	2.26%
TTKPRESTIG.NS	Dividend Junior	2023-07-21	Annually	20	0.43%
PLASTIBLEN.NS	Dividend Junior	2023-06-23	Annually	18	1.26%
JKTYRE.NS	Dividend Junior	2023-07-27	Annually	17	0.91%
DIAMONDYD.NS	Dividend Junior	2023-07-27	Annually	7	0.06%
360ONE.NS	Dividend Knight	2023-07-28	Semi-Annually	6	2.85%
SOMANYCERA.NS	Dividend Junior	2023-08-18	Annually	23	0.39%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0940	1.500	8.12	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.124	1.500	9.73	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	4.20	1.000	9.56	9.56	[3 - 30]
operatingCashFlowPerShareTTM	4.15	2.00	8.62	10.00	[0 - 30]
freeCashFlowPerShareTTM	4.15	2.00	7.93	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.486	1.000	5.24	5.24	[0.2 - 0.8]
operatingProfitMarginTTM	0.158	1.000	8.85	8.85	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.64

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	40.02	1.000	6.06	0	[1 - 100]
returnOnEquityTTM	0.124	2.50	9.83	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	4.15	2.00	8.62	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.15	2.00	8.62	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.956	1.500	6.96	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0430	1.000	-1.424	0	[0.1 - 0.5]
Total Score				4.46

Kilitch Drugs (India)

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.